Functional variants in CYP1B1, KRAS and MTHFR genes are associated with shorter telomere length in postmenopausal women

Mechanisms of Ageing and Development

Volumn 149, Issue , 2015, Pages 1-7

  Cerne, Jasmina Z ^a   Pohar Perme, Maja ^b   Cerkovnik, Petra ^c   Gersak, Ksenija ^a   Novakovic, Srdjan ^c  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Estrogen metabolism; Hormone replacement therapy; Oxidative stress; Polymorphism; Postmenopause; Telomere length

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 1B1; ESTROGEN; GESTAGEN; GLUTATHIONE TRANSFERASE P1; FOLIC ACID; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; COMT GENE; CONTROLLED STUDY; CYP1B1 GENE; ESTROGEN METABOLISM; FEMALE; FOLATE METABOLISM; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GSTP1 GENE; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; KRAS GENE; LEUKOCYTE; MNSOD GENE; MOLECULAR PATHOLOGY; MTHFR GENE; OXIDATIVE STRESS; POSTMENOPAUSE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; TELOMERE SHORTENING; TREATMENT DURATION; ALLELE; CASE CONTROL STUDY; CHEMISTRY; GENETIC VARIATION; GENETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; ONCOGENE RAS; TELOMERE; ULTRASTRUCTURE;

AGED; ALLELES; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1B1; ESTROGENS; FEMALE; FOLIC ACID; GENES, RAS; GENETIC VARIATION; GENOTYPE; HORMONE REPLACEMENT THERAPY; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; POSTMENOPAUSE; REAL-TIME POLYMERASE CHAIN REACTION; TELOMERE;

EID: 84930205472     PISSN: 00476374     EISSN: 18726216     Source Type: Journal    
DOI: 10.1016/j.mad.2015.05.003     Document Type: Article

References (55)

1. Andrew T., Aviv A., Falchi M., Surdulescu G.L., Gardner J.P., et al. Mapping genetic loci that determine leukocyte telomere length in a large sample of unselected female sibling pairs. Am. J. Hum. Gene 2006, 78:480-486.
2. Aviv A., Susser E. Leukocyte telomere length and the father's age enigma: implications for population health and for life course. Int. J. Epidemiol. 2013, 42:457-462.
3. Aviv A., Valdes A., Gardner J.P., Swaminathan R., Kimura M., et al. Menopause modifies the association of leukocyte telomere length with insulin resistance and inflammation. J. Clin. Endocrinol. Metab. 2006, 92:635-640.
4. Benetos A., Dalgard C., Labat C., Kark J.D., Verhulst S., et al. Sex difference in leukocyte telomere length is ablated in opposite -sex co -twins. Int. J. Epidemiol. 2014, 43(December (6)):1799-1805. 10.1093/ije/dyu146.
5. Blackburn E.H. Structure and function of telomeres. Nature 1991, 350:569-573.
6. Blasco M.A. Telomeres and human disease: ageing, cancer and beyond. Nat. Rev. Genet. 2005, 6:611-622.
7. Broer L., Codd V., Nyholt D.R., Deelen J., Mangino M., et al. Meta-analysis of telomere length in 19,713 subjects reveals high heritability, stronger maternal inheritance and a paternal age effect. Eur. J. Hum. Genet. 2013, 21:1163-1168.
8. Bull C.F., ÓCallaghan N.J., Mayrhofer G., Fenech M.F. Telomere length in lymphocytes of older South Australian men may be inversely associated with plasma homocysteine. Rejuvenation Res. 2009, 12:341-349.
9. Butler M.G., Tilburt J., DeVries A., Muralidhar B., Aue G., Hedges L., et al. Comparison of chromosome telomere integrity in multiple tissues from subjects at different ages. Cancer Genet. Cytogenet. 1998, 105:138-144.
10. Cavalieri E., Frenkel K., Liehr J.G., Rogan E., Roy D. Estrogens as endogenous genotoxic agents: DNA adducts and mutations. J. Natl. Cancer Inst. Monogr. 2000, 27:75-93.
11. Cawthon R.M. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002, 30:e47.
12. Cerne J.Z., Pohar-Perme M., Novakovic S., Frkovic-Grazio S., Stegel V., et al. Combined effect of CYP1B1, COMT, GSTP1, and MnSOD genotypes and risk of postmenopausal breast cancer. J. Gynecol. Oncol. 2011, 22:110-119.
13. Cerne J.Z., Stegel V., Gersak K., Novakovic S. Lack of association between methylentetrahydrofolate reductase genetic polymorphisms and postmenopausal breast cancer risk. Mol. Med. Rep. 2011, 4:175-179.
14. Cerne J.Z., Stegel V., Gersak K., Novakovic S. KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study. BMC Cancer 2012, 12:105-111.
15. Chin L.J., Ratner E., Leng S., Zhai R., Nallur S., et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008, 68:8535-8540.
16. Daniali L., Benetos A., Susser E., Kark J.D., Labat C., et al. Telomeres shorten at equivalent rates in somatic tissues of adults. Nature Commun. 2013, 4:1597. 10.1038/ncomms2602.
17. De Lange T. Protection of mammalian telomeres. Oncogene 2002, 21:532-540.
18. De Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005, 19:2001-2010.
19. De Vivo I., Prescott J., Wong J.Y., Kraft P., Hankinson S.E., et al. A prospective study of relative telomere length and postmenopausal breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 2009, 18:1152-1156.
20. Forges T., Monnier-Barbarino P., Alberto J.M., Gueant-Rodriguez R.M., Daval J.L., et al. Impact of folate and homocysteine metabolism on human reproductive health. Hum. Reprod. Update 2007, 13:225-238.
21. Friedrich U., Griese E., Schwab M., Fritz P., Thon K., Klotz U. Telomere length in different tissues of elderly patients. Mech. Ageing Dev. 2000, 119:89-99.
22. Fyhrquist F., Saijonmaa O., Standberg T. The roles of senescence and telomere shortening in cardiovascular disease. Nat. Rev. Cardiol. 2013, 10:274-283.
23. Greider C., Blackburn E.H. Identification of a specific terminal transferase activity in Tetrahymena extracts. Cell 1985, 51:887-898.
24. Haendeler J., Hoffmann J., Brandes R.P., Zeiher A.M., Dimmeler S. Hydrogen peroxide triggers nuclear export of telomerase reverse transcriptase via Src kinase family-dependent phosphorylation of tyrosine 707. Mol. Cell Biol. 2003, 23:4598-4610.
25. Hak A.E., Polderman K.H., Westendorp I.C., Jakobs C., Hofman A., et al. Increased plasma homocysteine after menopause. Atherosclerosis 2000, 149:163-168.
26. Kawanishi S., Oikawa S. Mechanism of oxidative stress by telomere shortening. Ann. N. Y. Acad. Sci. 2004, 1019:278-284.
27. Kim Y.I. Folate and carcinogenesis: evidence, mechanisms, and implications. J. Nutr. Biochem. 1999, 10:66-88.
28. Kyo S., Takakura M., Kanaya T., Zhuo W., Fujimoto K., et al. Estrogen activates telomerase. Cancer Res. 1999, 59:5917-5921.
29. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., et al. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996, 6:243-250.
30. Leal M., Diaz J., Serrano E., Abellan J., Carbonell L.F. Hormone replacement therapy for oxidative stress in postmenopausal women with hot flushes. Obstet. Gynecol. 2000, 95:804-809.
31. Lee D.C., Im J.A., Kim J.H., Lee H.R., Shim J.Y. Effect of long-term hormone therapy on telomere length in postmenopausal women. Yonsei Med. J. 2005, 46:471-479.
32. Li D.N., Seidel A., Pritchard M.P., Wolf C.R., Friedberg T. Polymorphisms in P450CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics 2000, 10:343-353.
33. Lin J., Kroenke C.H., Epel E., Kenna H.A., Wolkowitz O.M., et al. Greater endogenous estrogen exposure is associated with the telomere maintenance in postmenopausal women at risk for cognitive decline. Brain Res. 2011, 1379:224-231.
34. Liu J.J., Prescott J., Giovannucchi E., Hankinson S.E., Rosner B., et al. One-carbon metabolism factors and leukocyte telomere length. Am. J. Clin. Nutr. 2013, 97:794-799.
35. Loscalzo J. The oxidant stress of hyperhomocyst(e) inemia. J. Clin. Invest. 1996, 98:5-7.
36. Mitrunen K., Hirvonen A. Molecular epidemiology of sporadic breast cancer: the role of polymorphic genes involved in estrogen biosynthesis and metabolism. Mutat. Res. 2003, 544:9-41.
37. Mitrunen K., Kataja V., Eskelinen M., Kosma V.M., Kang D., et al. Combined COMT and GST genotypes and hormone replacement therapy associated breast cancer risk. Pharmacogenetics 2002, 12:67-72.
38. Morris M.S., Jacques P.F., Selhub J., Rosenberg I.H. Total homocysteine and estrogen status indicators in the third national health and nutritional examination survey. Am. J. Epidemiol. 2000, 152:140-148.
39. Nordfjall K., Larefalk A., Lindgren P., Holmberg D., Roos G. Telomere length and heredity: indications of paternal inheritance. Proc. Natl. Acad. Sci. U. S. A 2005, 102:16374-16378.
40. Park S.K., Yim D.S., Yoon K.S., Choi I.M., Choi J.Y., et al. Combined effects of GSTM1, GSTT1, and COMT genotypes in individual breast cancer risk. Breast Cancer Res. Treat. 2004, 88:55-62.
41. Parks C.G., Miller D.B., McCanlies E.C., Cawthon R.M., Andrew M.E., et al. Telomere length, current perceived stress, and urinary stress hormones in women. Cancer Epidemiol. Biomarkers Prev. 2009, 18:551-560.
42. Paul L., Cattaneo M., Dangelo A., Sampietro F., Fermo I., et al. Telomere length in peripheral blood mononuclear cells is associated with folate status in men. J. Nutr. 2009, 139:1273-1278.
43. Reding K.W., Weiss N.S., Chen C., Li C.I., Carlson C.S., et al. Genetic polymorphism pathway and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 2009, 18:1461-1467.
44. Richards J.B., Valdes A.M., Gardner J.P., Kato B.S., Siva A., et al. Homocysteine levels and leukocyte telomere length. Atherosclerosis 2008, 200:271-277.
45. Shen J., Terry M.B., Liao Y., Gurvich I., Wang Q., et al. Genetic variation in telomere maintenance genes, telomere length and breast cancer risk. PLoS One 2012, 7:e44308.
46. Somekawa Y., Kobayashi K., Tomura S., Aso T., Hamaguchi H. Effect of hormone replacement therapy and methylenetetrahydrofolate reductase polymorphism on plasma folate and homocysteine levels in postmenopausal Japanese women. Fertil. Steril. 2002, 77:481-486.
47. Song J.Y., Kim M.J., Jo H.H., Hwang S.J., Chae B., et al. Antioxidant effect of estrogen on bovine aortic endothelial cells. J. Steroid Biochem. Mol. Biol. 2015, 117:74-80.
48. Sutton A., Khoury H., Prip-Buus C., Cepanec C., Pessayre D., et al. The Ala16Val genetic polymorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 2003, 13:145-157.
49. Tallova J., Tomandl J., Bicikova M., Hill M. Changes of plasma total homocysteine levels during the menstrual cycle. Eur. J. Clin. Invest. 1999, 29:1041-1044.
50. Tsuchiya Y., Nakajima M., Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005, 227:115-124.
51. Valdes A.M., Andrew T., Gardner J.P., Kimura M., Oelsner E., et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005, 366:662-664.
52. Yager J.D. Endogenous estrogens as carcinogens through metabolic activation. J. Natl. Cancer Inst. Monogr. 2000, 27:67-73.
53. Yue W., Santen R.J., Wang J.P., Li Y., Verderame M.F., et al. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J. Steroid Biochem. Mol. Biol. 2003, 86:477-486.
54. Zimniak P., Nanduri B., Pikula S., Bandorowicz-Pikula J., Singhal S.S., et al. Naturally occurring human glutathione S-transferase GSTP 1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem 1994, 224:893-899.
55. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem. Sci. 2002, 27:339-344.